Table 3.
Variable 1 | Variable 2 | All grade VAHL | Grade 3–4 VAHL | ||||
---|---|---|---|---|---|---|---|
Pv | OR | 95% CI | Pv | OR | 95% CI | ||
(Numbers refer to variable 2) | (Numbers refer to variable 2) | ||||||
Interval between vaccination and imaging (days) | Gender (female) | 0.10 | 1.91 | 0.89–4.11 | 0.31 | 1.85 | 0.57–6.06 |
Age (years) | 0.01* | 0.93 | 0.89–0.98 | 0.01* | 0.92 | 0.86–0.98 | |
BMI (kg/m2) | 0.08 | 1.01 | 0.99–1.17 | 0.10 | 0.88 | 0.76–1.03 | |
Hematologic malignancies | 0.41 | 0.64 | 0.23–1.83 | 0.42 | 0.40 | 0.04–3.77 | |
Lower gastrointestinal cancers | 0.58 | 0.74 | 0.26–2.10 | 0.72 | 0.74 | 0.14–3.96 | |
Breast cancer | 0.83 | 1.12 | 0.39–3.25 | 0.38 | 0.37 | 0.04–3.29 | |
Lung cancers | 0.90 | 1.07 | 0.36–3.22 | 0.62 | 0.65 | 0.12–3.56 | |
Skin cancers and sarcomas | 0.15 | 0.40 | 0.11–1.39 | 0.43 | 0.41 | 0.04–3.79 | |
Hepatobiliary-pancreatic cancers | 0.23 | 2.29 | 0.59–8.93 | 0.08 | 4.80 | 0.84–27.32 | |
Gynecological cancers | 0.23 | 2.67 | 0.53–13.33 | 0.58 | 1.77 | 0.23–13.59 | |
Genitourinary cancers | 0.94 | 0.94 | 0.19–4.58 | 0.99 | - | - | |
Upper gastrointestinal cancers | 0.94 | 1.07 | 0.18–6.32 | 0.14 | 5.30 | 0.58–48.46 | |
Head and neck cancers | 0.65 | 1.89 | 0.12–30.54 | 0.15 | 8.69 | 0.46–162.69 | |
Active malignancy | 0.50 | 0.74 | 0.31–1.77 | 0.46 | 1.72 | 0.41–7.26 | |
Recent systemic anti-cancer therapy | 0.30 | 0.66 | 0.30–1.45 | 0.43 | 1.59 | 0.50–5.04 | |
Recent chemotherapy | 0.77 | 0.87 | 0.35–2.18 | 0.22 | 2.12 | 0.65–6.91 | |
Recent biologic therapy | 0.41 | 0.68 | 0.27–1.71 | 0.78 | 0.81 | 0.19–3.46 | |
Recent immunotherapy | 0.57 | 0.64 | 0.14–2.92 | 0.26 | 2.91 | 0.45–18.80 |
Each parameter was analyzed together with the time interval between vaccination and imaging on a bivariable logistic regression. Analyses were performed for the prediction of all-grade VAHL and grade 3–4 VAHL. The odds ratio (OR) with 95% confidence interval (CI) for each analyzed variable are presented for the prediction of all-grade VAHL and grade 3–4 VAHL. VAHL, vaccine-associated hypermetabolic lymphadenopathy; BMI, body mass index. Active malignancy, this variable was considered positive in cases of treatment-naïve patients, those who received recent anti-cancer therapy, and those with recurrent disease identified on their [18F]FDG PET-CT scan. Recent therapy was considered if given during the 3 months before the scan